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Purpose: The metabolic syndrome (MS) has been accepted as an important cause of be-
nign prostatic hyperplasia (BPH) in old age. However, there are no studies of the influ-
ence of MS on prostate volume in relatively young adults. We evaluated the relationship 
between parameters of MS and prostate volume in men under 50 years of age who visited 
our health promotion center.
Materials and Methods: A total of 968 men aged 30 to 49 years were enrolled from March 
2009 to June 2010. Prostate volume by transrectal ultrasonography of the prostate, 
serum prostate-specific antigen, digital rectal examination, urinalysis, and MS-related 
parameters were investigated. We evaluated the correlations of prostate volume with 
MS and MS-related parameters.
Results: Prostate volume was not significantly larger in the MS group (18.4 cc; range: 
14.3-23.1 cc) than in the non-MS group (17.8 cc; range, 13.6-21.6 cc). The prostate vol-
umes in subjects with abnormal fasting plasma glucose (FPG) (18.9 cc; range, 14.3-22.7 
cc) and abnormal waist circumference (WC) (19.5 cc; range, 15.6-23.7 cc) were significantly 
larger than those of subjects with normal parameters (16.9 [range, 12.7-20.4] cc and 
17.5 [range, 13.3-21.2] cc, respectively; p=0.001). The logistic regression analysis showed 
the FPG level and WC to have a significantly positive correlation with the prostate volume 
(odds ratios: 1.441 [95% CI: 1.303-1.643] and 2.305 [95% CI: 1.470-3.614], respectively). 
Conclusions: Groups with abnormal FPG and WC had larger prostate volumes than 
did normal groups. The abnormal FPG and WC could be more important factors than 
MS in prostate volume enlargement in relatively young adults.
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INTRODUCTION
As the common benign tumor in male, benign prostatic hy-
perplasia (BPH) develops as a age-related phenomenon in 
almost all men, starting at approximately 40 years of age. 
Clinically, BPH leads to a progressive enlargement of the 
prostate gland, causing both obstructive and irritative low-
er urinary tract symptoms (LUTS). The lifetime risk for a 
50-year-old man to undergo a prostatectomy for BPH has 
been estimated to be as high as 40% [1].
　BPH is a specific histopathologic entity characterized by 
stromal and epithelial cell hyperplasia. For over a century, 
there have been two known etiologic factors for the patho-
genesis of BPH: aging and androgens [2]. Moreover, family 
history, ethnicity, smoking, type II diabetes mellitus (DM), 
high-density lipoprotein cholesterol (HDL-C), high insulin 
content, high blood pressure, and obesity have been re-
ported to be risk factors [3].
　Many reports have discussed the correlations of meta-
bolic syndrome (MS) and prostate volume. However, de-
spite such existing epidemiological and pathophysiologic 
evidence, there are many disputes in considering MS as a 
risk factor for BPH. One of the reasons for this dispute is 
the paucity of large epidemiological studies. Another rea-
son is that most studies that analyzed the relationship be-
tween MS and BPH were conducted in older men more than Korean J Urol 2011;52:390-395
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TABLE 1. Comparisons of metabolic factors and prostate volume 
according to age groups
All subjects 30-39 years  40-49 years  Characteristics (n=848) (n=278) (n=570)
Age (yr) 41.4±5.2 35.2±3.0 44.4±2.9
BP (mmHg)
　Systolic 117.8±11.1 118.0±11.4 118.0±11.0
　Diastolic 75.3±8.5 75.0±8.4 75.4±8.4
FPG (mg/dl)   99.7±17.2   97.2±17.0 101.0±17.1
WC (cm) 84.7±7.2 83.7±7.4 85.2±7.0
HDL-C (mg/dl)   51.7±10.7   52.3±10.7   51.4±10.7
TG (mg/dl) 134.0±77.6 126.1±71.3 137.9±80.3
PV (cc) 18.4±6.3 17.0±5.7 19.1±6.5
PSA (ng/ml)   1.0±0.6   1.0±0.6   1.0±0.6
BP: blood pressure, FPG: fasting plasma glucose, WC: waist cir-
cumference, HDL-C: high-density lipoprotein cholesterol, TG: tri-
glyceride, PV: prostate volume, PSA: prostate-specific antigen
50 years of age.
　Therefore, unlike the previous studies that reviewed 
BPH and MS in old age groups, in the present study, we ana-
lyzed its associations with MS and components of MS by 
investigating the prostate volume of relatively healthy, 
young male subjects (in their fourth to fifth decades) with-
out underlying disease.
MATERIALS AND METHODS
1. Study population
Among 75,368 men older than 30 and younger than 50 
years of age who came to the Health Promotion Center at 
the Kangbuk Samsung Hospital for a routine health check-
up between March 2009 and June 2010, data were retro-
spectively obtained from 986 men who underwent trans-
rectal ultrasonography (TRUS) of the prostate. TRUS was 
performed in subjects who came to the Health Promotion 
Center as part of a basic examination included in a health 
screening program or as a test selected by the subjects them-
selves. The health screening program available at our Health 
Promotion Center includes anthropometric measurements 
(height, weight, and waist circumference [WC]), blood test 
(a complete blood cell count, basic chemistry, serologic test, 
blood coagulation test, thyroid function test, and assay for 
tumor markers), stool/urine analysis, abdominal ultra-
sonography, gastrofiberscopy, chest radiography, pulmo-
nary function test, electrocardiography, and detailed clin-
ical examination. All subjects were also asked to complete 
a questionnaire designed to assess sociodemographic fac-
tors, comorbidities, and current or past medications. The 
Institutional Review Board of the Kangbuk Samsung Hos-
pital approved all the procedures involved in sampling and 
data collection, and written informed consent was obtained 
from all participants. Among the 986 men, 138 men were 
excluded from the study for reasons including taking medi-
cations for BPH (n=47), having a history of type I insulin- 
dependent DM (n=22), having abnormal serum prostate- 
specific antigen (PSA) (≥4 ng/ml; n=11), or having a suspi-
cion of prostate cancer by TRUS or digital rectal examina-
tion (DRE; n=1). In addition, 57 men showing pyuria on uri-
nalysis were excluded from the study.
2. Measures
Metabolic syndrome was defined by using the criteria es-
tablished by the National Cholesterol Education Program- 
Adult Treatment Panel III-American Heart Association/ 
National Heart, Lung, and Blood Institute (NCEP-ATPIII- 
AHA/NHLBI) statement, published in 2005 [4]. Central 
obesity was defined as WC ≥90 cm in men or ≥80 cm in 
women by the modified ATP III guideline that the WHO- 
Western Pacific Region (WPR) and the International 
Association for the Study of Obesity (IASO) presented for 
Asian populations in 2000. MS was diagnosed when at least 
three of the following criteria were present: WC of ≥90 cm, 
triglyceride (TG) levels of ≥150 mg/dl or undergoing treat-
ment for hypertriglyceridemia, HDL-C levels of ＜40 mg/dl 
or undergoing treatment for low HDL-C, blood pressure 
(BP) of ≥130/85 mm Hg or undergoing treatment for hyper-
tension, and fasting plasma glucose (FPG) of ≥100 mg/dl 
or undergoing treatment for hyperglycemia. 
　All parameters were measured on fresh serum obtained 
after the subjects had fasted for 12 hours overnight. Serum 
total cholesterol, TG, HDL-C, and FPG were measured by 
enzymatic methods. Serum PSA values were measured by 
using a Tandem-R PSA immunoradiometric assay. The 
prostate volume was calculated according to the prostate 
ellipsoid formula, multiplying the largest anteroposterior 
(height, H), transverse (width, W), and cephalocaudal 
(length, L) prostate diameters by 0.524 (HxWxLx π/6) by 
using TRUS (ALOKA
Ⓡ, prosound-α5sv).
3. Statistical analysis
All analyses were performed by using the PASW ver. 17.0 
(SPSS Inc., Chicago, IL, USA). Associations were assessed 
between each of the metabolic components, as well as MS, 
and prostate volume. Prostate volumes were compared in 
men with and without MS, and with and without each met-
abolic component, by using the Mann-Whitney U-test. A p 
value of less than 0.05 was deemed as significant. Conti-
nuous variables were expressed as the mean±standard de-
viation (SD), and because most variables in this report were 
not normally distributed, we preferred to use nonpara-
metric statistics, namely, the median value. A multiple lo-
gistic regression model was performed to examine the asso-
ciation between MS and prostate volume. We used the risk 
ratio with 95% confidence intervals (CIs) to evaluate the 
association between significant variables and prostate 
volume. Adjusted odds ratios (ORs) with accompanying 
95% CIs are reported. 
RESULTS
The mean age of the entire subject population was 41.4±5.2 
years. The mean prostate volume in all subjects was 18.4± Korean J Urol 2011;52:390-395
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Characteristics
All subjects (n=848) 30-39 years (n=278) 40-49 years (n=570)
n PV p-value n PV p-value n PV p-value
MS
  MS
  Non-MS
BP
  Abnormal
  Normal
SBP
  Abnormal
  Normal
DBP
  Abnormal
  Normal
FPG
  Abnormal
  Normal
WC
  Abnormal
  Normal
HDL-C
  Abnormal
  Normal
TG
  Abnormal
  Normal
140 18.4 (14.3-23.1)
0.225
  35 18.1 (13.1-24.1)
0.069
105 18.6 (14.5-23.0)
0.890
708 17.8 (13.6-21.6) 243 16.2 (12.6-20.2) 465 18.8 (14.6-22.6)
216 17.5 (13.5-21.8)
0.435
  70 17.5 (12.9-21.1)
0.360
146 17.6 (13.6-22.0)
0.123
632 18.1 (13.8-21.7) 208 16.2 (12.6-20.4) 424 18.9 (14.9-22.8)
183 17.5 (13.6-21.7)
0.539
  63 17.6 (13.2-22.0)
0.238
120 17.5 (13.8-21.6)
0.143
665 18.0 (13.7-21.8) 215 16.2 (12.6-20.3) 450 18.9 (14.7-22.8)
106 18.1 (13.8-21.6)
0.917
  30 18.1 (12.0-21.1)
0.589
  76 18.0 (14.3-22.0)
0.808
742 17.9 (13.7-21.7) 248 16.2 (12.7-20.4) 494 18.8 (14.6-22.7)
331 18.9 (14.3-22.7)
 0.001
a   77 17.3 (13.0-20.9)
 0.017
a 254 19.8 (15.8-24.0)
 0.001
a
517 16.9 (12.7-20.4) 201 15.1 (11.5-18.6) 316 17.2 (13.4-20.5)
173 19.5 (15.6-23.7)
 0.001
a   45 19.0 (15.5-22.3)
 0.001
a 128 19.9 (16.0-23.7)
 0.005
a
675 17.5 (13.3-21.2) 233 16.1 (12.3-19.9) 442 18.3 (14.1-21.8)
87 18.9 (13.8-22.6)
0.431
  25 18.4 (12.8-21.5)
0.428
  62 19.0 (14.2-23.2)
0.866
761 17.8 (13.7-21.7) 253 16.6 (12.6-20.2) 508 18.7 (14.6-22.6)
251 18.2 (14.3-22.6)
0.212
  72 17.1 (12.7-23.4)
0.137
179 18.6 (14.7-22.6)
0.984 597 17.8 (13.5-21.4) 206 16.5 (12.6-20.0) 391 18.8 (14.3-22.6)
MS: metabolic syndrome, BP: blood pressure, SBP: systolic blood pressure, DBP: diastolic blood pressure, FPG: fasting plasma glucose, 
WC: waist circumference, HDL-C: high density lipoprotein, TG: triglyceride, 
a: p＜0.05 by Mann-Whitney U test
TABLE 2. Comparisons of prostate volume according to MS and MS parameters
TABLE 3. Independent predictors of enlarged prostate volume (≥
20 cc) using a multiple logistic regression analysis according to 
age group
Age-adjusted OR 95% CI p-value
All subjects
   FPG ≥100 mg/dl 1.441 1.303-1.643 0.001
   WC ≥90 cm 2.305 1.470-3.614 0.001
30-39 years
   FPG ≥100 mg/dl 1.377 1.176-1.810 0.012
   WC ≥90 cm 2.751 1.213-6.241 0.015
40-49 years
   FPG ≥100 mg/dl 1.488 1.311-1.767 0.002
   WC ≥90 cm 2.129 1.227-3.694 0.007
OR: odds ratio, CI: confidence interval, FPG: fasting plasma glu-
cose, WC: waist circumference
6.3 cc. The mean value of each component of MS and PSA 
are shown in Table 1. 
　The prostate volume was not significantly larger in the 
MS group. The median prostate volumes in the MS and 
non-MS groups were 18.4 cc (range, 14.3-23.1 cc) and 17.8 
cc (range, 13.6-21.6 cc), respectively. There was no statisti-
cally significant difference between the two groups (p＞
0.05). In addition, there were no statistically significant 
differences in the prostate volume according to the pres-
ence of MS in the two age subgroups (30-39 and 40-49 years; 
Table 2).
　Men with abdominal obesity (WC≥90 cm) and men with 
abnormal FPG levels (≥100 mg/dl) had a larger prostate 
volume than did the normal control group. The median 
prostate volumes in the abdominal obesity group and the 
normal WC group were 19.5 cc (range, 15.6-23.7 cc) and 17.5 
cc (range, 13.3-21.2 cc), respectively (p＜0.05). The pros-
tate volumes according to normal and abnormal FPG level 
were 16.9 cc (range, 12.7-20.4 cc) and 18.9 cc (range, 14.3- 
22.7 cc), respectively (p＜0.05). When the prostate volume 
was further analyzed according to age subgroups, the pros-
tate volumes in men with abdominal obesity or abnormal 
FPG levels were also significantly larger than in the nor-
mal control groups (p＜0.05) (Table 2).
　The results of the multivariate analysis after adjust-
ment for age and each MS factor showed that abdominal 
obesity (OR=2.305; 95% CI: 1.470-3.614, p=0.001) and an 
abnormal FPG level (OR=1.441; 95% CI: 1.303-1.643, 
p=0.001) were strongly associated with enlarged prostate 
volume (≥20 cc) (Table 3).
DISCUSSION
In the United States, the prevalence rate of MS has been 
reported variously ranging from 2.4% to 43.5%. According Korean J Urol 2011;52:390-395
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to data reported in United States in 2005, the prevalence 
rate of MS according to the NCEP-ATP III criteria reached 
34.6%, and a prevalence rate of 28% was reported when the 
same criteria were applied in Korea [5].
　MS is a constellation of multiple metabolic and cardio-
vascular disease risk factors, at the center of which is in-
sulin resistance (a state in which muscle, liver, and fat tis-
sues have reduced sensitivity to insulin) and compensatory 
hyperinsulinemia. Investigators have reported a strong in-
fluence of age on the presence of MS, which affects 43.5% 
of those aged 60 to 69 years [6]. Similarly, BPH is seen fre-
quently in males older than 50 years. About 60% of men 
aged over 50 years have histological evidence of BPH and, 
after age 70, the proportion increases to 80% [7]. Histori-
cally, the development of BPH focused on the interplay be-
tween genetic and hormonal factors. More recently, how-
ever, a growing body of evidence has demonstrated a strong 
and independent link between BPH and obesity and MS. 
This relationship has implications for the pathophysiology 
and treatment of these disorders. Furthermore, this associ-
ation implies that modifiable risk factors may play a role 
in the pathogenesis of these entities [8].
　Despite the high prevalence of BPH in aged men, our un-
derstanding of the disease pathogenesis is far from com-
plete. Although the etiology of BPH is not well understood, 
several theories have been proposed to explain the patho-
genesis of BPH [9]. Testosterone-dihydrotestosterone (DHT) 
signaling and mesenchymal-epithelial interactions are re-
quired for normal prostaticgrowth and are known to play 
an important role in the progression of disease [10]. Many 
risk factors for BPH, such as insulin, insulin-like growth 
factors (IGFs), and dyslipidemia, might act through an-
drogen-independent mechanisms [11,12].
　The underlying cause of MS also continues to challenge 
experts, but both insulin resistance and central obesity are 
considered to be significant factors [13]. Recent studies 
suggest that hyperinsulinemia secondary to insulin resist-
ance and the components of MS are risk factors for the de-
velopment of BPH [14-16]. Furthermore, MS may play a 
role in BPH pathogenesis. Several experimental and clin-
ical reports indicate the critical role of obesity and insulin- 
resistance-associated complications in the pathogenesis of 
BPH [3,15,17,18]. The increased incidence of BPH in in-
sulin-resistant and diabetic populations strengthens the 
relationship between these two pathological conditions 
and makes this an increasingly relevant problem [19]. 
Insulin resistance is a condition in which a normal level of 
insulin elicits a subnormal response. It is a condition that 
is associated with a group of disorders such as obesity, dys-
lipidemia, elevated fasting glucose level, hyperinsulinemia, 
and hypertension. In addition to type 2 DM and cardiovas-
cular disease, patients with insulin resistance syndrome 
are at higher risk for BPH [20]. Some isolated reports op-
pose the view regarding the relationship between insulin 
resistance and BPH [21,22]. 
　The insulin-resistance-associated disorders such as obe-
sity, dyslipidemia, hypertension, sympathetic overactivity, 
and hyperinsulinemia have been implicated in the patho-
genesis of BPH. The prevalence of obesity is increasing all 
over the world due to sedentary lifestyles. Obesity has been 
implicated in the etiology of BPH because of its inﬂuence 
on metabolic and endocrine changes. Recent ﬁndings in-
dicate that obesity substantially increases the risk for 
BPH. In the study conducted by Dahle et al, an increased 
serum insulin level was related to increased BPH risk, and 
Parson et al reported the correlations of prostate volume 
with body mass index, elevated fasting blood sugar level, 
and DM [16,17]. The Health Professionals Follow-up Study, 
a prostate cancer prevention trial, and a case-control study 
of Italian men showed a positive association between obe-
sity and BPH [16]. The fasting serum level of insulin in the 
patients with higher waist-to-hip ratio was signiﬁcantly 
high, indicating the involvement of insulin in the pro-
gression of disease [16]. Several independent studies have 
further supported the association between obesity and hy-
perinsulinemia [23,24]. In a population-based study con-
ducted in Korea, Jang et al reported that there was a sig-
nificant correlation between each MS factor and prostate 
volume [25]. Koo et al also reported that MS is associated 
with prostate volume-related factors, but not to voiding 
dysfunction in Korean men 60 years of age or older. Among 
the subcategories of MS, they reported that obesity is the 
factor most strongly related to prostate volume [26]. Few 
reports argue that obesity is associated with increased es-
trogen-to-androgen ratio and sympathetic activity, both of 
which are individually hypothesized to promote the devel-
opment of prostatic hyperplasia [14]. 
　Obesity can augment prostatic growth either by promot-
ing the development of insulin resistance and secondary 
hyperinsulinemia or by increasing the estrogen-to-andro-
gen ratio. One more pathway that explains the increased 
risk for BPH in hyperinsulinemia is the IGF axis. IGF-1 is 
a strong mitogen and increases cell proliferation and in-
duces apoptosis in many tissues, including prostatic stro-
ma and epithelium [27].
　In this study, we found that obesity and DM were risk 
factors for BPH in young men, but the presence of MS was 
not. According to the study of Gupta et al, MS had no con-
tributing effect on BPH in a prospective study of the causal 
relationship of MS and BPH through long-term follow-up 
observation (mean of 15.6 years) [21]. The results should 
be interpreted with caution, however. Several studies have 
postulated that MS and BPH may be related [3,28]. Our re-
port is the only study to assess whether relatively young 
men with MS had an increased risk of BPH, and we found 
no relationship between the two. Apart from abnormal 
FPG and obesity, none of the other markers of the MS were 
associated with an increased risk of BPH. The results from 
other prospective studies have not shown a consistent rela-
tionship between any of the MS markers and BPH [14,29]. 
Thus, considering the evidence from the longitudinal stud-
ies, it is unlikely that a causative association exists be-
tween the MS and BPH. 
　We did not find any relationship between prostate volume Korean J Urol 2011;52:390-395
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and HDL-C or TG. In the study conducted by Rohrmann 
et al using data from NHANES III, they also did not ﬁnd 
any relationship between LUTS and HDL-C, low density 
lipoprotein, TG, or total cholesterol. Overall, dyslipidemia 
is likely to have a limited role, if any, in the etiology of BPH.
　We also did not find any relationship between prostate 
volume and BP. In contrast, Gann et al, in a smaller pro-
spective study involving 640 men, found an increased odds 
of BPH with a higher diastolic BP and no effect with systolic 
BP. The mechanism of the association between BP and 
BPH/LUTS remains unknown, but a role of sympathetic 
tone has been hypothesized [30].
　Unlike the previous studies, the present study analyzed 
the substantial correlations of BPH with MS in relative 
younger men aged 30 to 49 years. The present data show 
the possibility of young adults with obesity or DM having 
a larger prostate volume, which is similar to the clinical ob-
servation that men suffering from DM and obesity have a 
larger prostate gland volume than do men without these 
conditions at old ages. According to the study of Berry et 
al, the prostate volume doubling time was 4.5 years among 
BPH patients aged 30 to 50 years, but the reported the dou-
bling times of the patients aged 50-71 years was 10 years 
and that of patients aged more than 70 years was 100 years. 
Also, they also reported that a fast growth speed of prostate 
volume in younger men with BPH [7]. This study suggests 
that it is possible that the elements of MS may have differ-
ent effects on the younger and the older. Also, if young men 
have obesity and DM, they are predisposed to early and se-
vere development of BPH owing to the effect of obesity and 
DM on the naturally rapidly growing prostate compared 
with old men. Therefore, more caution is needed when 
young men have obesity and DM for early diagnosis and 
treatment of BPH. Also, modification of lifestyles and high- 
fat diets in young men with obesity and DM are needed to 
prevent the development of BPH.
　In our study, the analyses were cross-sectional, and thus 
causal and longitudinal relations were not addressed. 
There was the potential for selection bias because the sub-
jects were the populations who visited the health promo-
tion center for routine medical examination and not for the 
treatment or diagnosis of LUTS/BPH. Also, we did not con-
sider the subject’s lifestyle patterns of diet habits, exercise, 
and hormonal status including testosterone. Despite the 
aforementioned limitations, however, this study is val-
uable in that it proposed the possibility of early or severe 
BPH development in young men with obesity or DM.
CONCLUSIONS
In young men aged 30 to 49 years old, the presence of MS 
was not correlated with prostate volume. However, men 
with abnormal FPG and WC had larger prostates than did 
normal groups. The risk of prostate enlargement increased 
with increasing FPG and WC. Obesity and DM could be 
more important factors than MS in prostate volume en-
largement in relatively young adults. 
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